SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IVPH -- INNOVIVE Pharmaceuticals
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: bookert11 who wrote (72)2/20/2008 2:35:14 PM
From: stunner  Read Replies (1) of 117
 
I think the company has good compounds. As mentioned, tambarotene is already approved in Japan. Even though it faces competition, 406 is targeted at a large market and $100 mil in sales could easily be obtainable. Once the SPA is in effect, it should only take $30 mil in trials to take it to NDA.

I am unimpressed with management and with the board. I can't fathom how they weren't able to raise at least a few mil long before it came to this ridiculous situation. I think the last financing's caveat that investors would receive extra shares if the follow-on raise occurred at a lower price was a disaster.

So, any thoughts on a possible buyout price? If they do raise $4 mil, will it be at current share valuation or at 1-1.50?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News